Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Sestak

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
British Journal of Cancer|January 26, 2021
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialIvana Sestak, Glen Blake, Raj Patel, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Journal of the National Cancer Institute|February 22, 2007
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trialJack Cuzick, John F Forbes, Ivana Sestak, et al.
Breast Cancer Research and Treatment|July 16, 2013
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC studyMaria Afentakis, Mitch Dowsett, Ivana Sestak, et al.
Journal of the National Cancer Institute|September 14, 2013
Factors predicting late recurrence for estrogen receptor-positive breast cancerIvana Sestak, Mitch Dowsett, Lila Zabaglo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast CancerIvana Sestak, Yi Zhang, Brock E Schroeder, et al.
Breast Cancer Research and Treatment|March 3, 2021
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention StudiesSamuel G Smith, Ivana Sestak, Michelle A Morris, et al.
The Lancet. Oncology|August 16, 2008
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysisIvana Sestak, Jack Cuzick, Francisco Sapunar, et al.
Cancer Treatment Reviews|July 22, 2011
Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic reviewJavaid Iqbal, Ophira M Ginsburg, Thiwanka D Wijeratne, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
British Journal of Cancer|January 26, 2021
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trialIvana Sestak, Glen Blake, Raj Patel, et al.
The Lancet. Oncology|November 20, 2010
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialJack Cuzick, Ivana Sestak, Michael Baum, et al.
The Lancet. Oncology|December 16, 2014
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trialJack Cuzick, Ivana Sestak, Simon Cawthorn, et al.
Journal of the National Cancer Institute|February 22, 2007
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trialJack Cuzick, John F Forbes, Ivana Sestak, et al.
Breast Cancer Research and Treatment|July 16, 2013
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC studyMaria Afentakis, Mitch Dowsett, Ivana Sestak, et al.
Journal of the National Cancer Institute|September 14, 2013
Factors predicting late recurrence for estrogen receptor-positive breast cancerIvana Sestak, Mitch Dowsett, Lila Zabaglo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast CancerIvana Sestak, Yi Zhang, Brock E Schroeder, et al.
Breast Cancer Research and Treatment|March 3, 2021
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention StudiesSamuel G Smith, Ivana Sestak, Michelle A Morris, et al.
The Lancet. Oncology|August 16, 2008
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysisIvana Sestak, Jack Cuzick, Francisco Sapunar, et al.
Cancer Treatment Reviews|July 22, 2011
Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic reviewJavaid Iqbal, Ophira M Ginsburg, Thiwanka D Wijeratne, et al.
Pageof 7